Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Prasugrel (Efient) is a potent, selective and irreversible inhibitor of adenosine diphosphate (ADP)-mediated platelet aggregation that is indicated for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS) [comprising unstable angina pectoris/non-ST-segment-elevation myocardial infarction (unstable angina/NSTEMI) and ST-segment-elevation myocardial infarction (STEMI)] undergoing percutaneous coronary intervention (PCI). Oral prasugrel provides rapid, potent inhibition of platelet aggregation and is an effective antiplatelet agent for the management of patients with ACS who are undergoing PCI. In these patients, prasugrel was associated with a significantly lower incidence of ischaemic events than clopidogrel, and was particularly effective in specific subgroups of patients, such as those with diabetes mellitus. However, the efficacy of prasugrel was offset by a higher risk of bleeding than clopidogrel, with patients aged > or =75 years, those weighing <60 kg and those with a history of stroke or transient ischaemic attack at the greatest risk. A lower dose of prasugrel in patients aged > or =75 years and those weighing <60 kg may help to minimize the bleeding risk, although more data are needed to establish this; prasugrel is contraindicated in patients with a history of stroke or transient ischaemic attack. Thus, prasugrel provides a new option for the management of patients with ACS who are undergoing PCI; the risk-benefit ratio should be carefully assessed before intensive antiplatelet therapy with prasugrel is initiated.
Duggan
Sean T
ST
Wolters Kluwer Health/Adis, 41 Centorian Drive, Mairangi Bay, North Shore 0754, Auckland, New Zealand. demail@adis.co.nz
Keating
Gillian M
GM
D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000601:surgery*; D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D016063:Blood Loss, Surgical / Q000503:physiopathology; D000077144:Clopidogrel; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000068799:Prasugrel Hydrochloride; D016032:Randomized Controlled Trials as Topic; D013876:Thiophenes / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014018:Tissue Distribution; D055815:Young Adult
D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D013876:Thiophenes; D000077144:Clopidogrel; D000068799:Prasugrel Hydrochloride; D013988:Ticlopidine
J Am Coll Cardiol. 2007 Apr 10;49(14):1505-16
17418288
Platelets. 2006 Jun;17(4):209-17
16769598
J Clin Pharmacol. 2008 Apr;48(4):475-84
18303127
J Cardiovasc Pharmacol. 2007 Mar;49(3):167-73
17414229
Circulation. 2008 Jan 15;117(2):261-95
18079354
Am Heart J. 2006 Oct;152(4):627-35
16996826
Circulation. 2009 May 19;119(19):2553-60
19414633
J Am Coll Cardiol. 2001 Dec;38(7):2114-30
11738323
Lancet. 2008 Apr 19;371(9621):1353-63
18377975
Med J Aust. 2008 Apr 7;188(7):381-2
18393737
Lancet. 2009 Feb 28;373(9665):723-31
19249633
Semin Thromb Hemost. 2005 Apr;31(2):184-94
15852222
Am J Cardiol. 2009 Feb 2;103(3 Suppl):4A-10A
19166707
Am J Med. 2009 May;122(5):407-8
19375544
Clin Cardiol. 1999 Nov;22(11):687-98
10554682
Circulation. 2005 May 24;111(20):2557-9
15911717
Eur Heart J. 2008 Oct;29(20):2473-9
18682445
N Engl J Med. 2007 Nov 15;357(20):2078-81
17982183
Br J Clin Pharmacol. 2007 Apr;63(4):421-30
17076696
Am J Cardiovasc Drugs. 2005;5(6):399-408
16259528
JAMA. 2007 Aug 15;298(7):765-75
17699010
Eur Heart J. 2008 Jan;29(1):21-30
18055486
Eur Heart J. 2007 Jul;28(13):1598-660
17569677
Eur Heart J. 2005 Apr;26(8):804-47
15769784
Am J Cardiovasc Drugs. 2007;7(6):423-32
18076209
N Engl J Med. 2009 Jan 22;360(4):354-62
19106084
Clin Pharmacol Ther. 2007 May;81(5):735-41
17361128
Drug Metab Dispos. 2008 Jul;36(7):1227-32
18372401
J Cardiovasc Pharmacol. 2007 Nov;50(5):555-62
18030066
Circ Res. 2007 May 11;100(9):1261-75
17495233
J Thromb Haemost. 2008 Nov;6(11):1908-14
18752581
Circulation. 2008 Jan 15;117(2):296-329
18071078
Circulation. 2007 Aug 14;116(7):e148-304
17679616
N Engl J Med. 2007 Nov 15;357(20):2001-15
17982182
Circulation. 2009 Jun 2;119(21):2758-64
19451347
Drugs. 2007;67(4):613-46
17352522
Eur J Pharmacol. 2008 Jan 28;579(1-3):276-82
17996866
Curr Med Res Opin. 2008 Aug;24(8):2251-7
18786302
Thromb Haemost. 2005 Sep;94(3):593-8
16268477
Am J Cardiol. 2009 Feb 2;103(3 Suppl):40A-51A
19166712
Circulation. 2008 Oct 14;118(16):1626-36
18757948
Eur Heart J. 2007 Oct;28(20):2525-38
17951287
Thromb Haemost. 2009 Jan;101(1):14-22
19132184
Drug Metab Dispos. 2007 Jul;35(7):1096-104
17403916
J Am Coll Cardiol. 2008 May 27;51(21):2028-33
18498956
J Thromb Haemost. 2007 Dec;5(12):2429-36
17900275
Am Heart J. 2007 Jan;153(1):66.e9-16
17174640
Eur Heart J. 2006 May;27(10):1166-73
16621870
Am Heart J. 2008 Aug;156(2 Suppl):S3-9
18657680
Circulation. 2007 Dec 18;116(25):2923-32
18056526
Drug Metab Dispos. 2006 Apr;34(4):600-7
16415119
J Thromb Haemost. 2007 Jul;5(7):1545-51
17456192
Lancet. 2004 Jul 24-30;364(9431):331-7
15276392
Circulation. 2005 Jun 28;111(25):3366-73
15967851
J Am Coll Cardiol. 2008 Dec 9;52(24):1968-77
19055987
Am Heart J. 2008 Aug;156(2 Suppl):S16-22
18657682
Circulation. 2008 Oct 14;118(16):1607-8
18852375
Am J Cardiol. 2009 Feb 2;103(3 Suppl):27A-34A
19166710